Menu
Home
In the news
Company Our Team Board of Directors Collaborations and Partnering
Our Platform About AMT-143 Publications Frequently Asked Questions
Pipeline
Careers
Contact Us

AmacaThera

AmacaThera · Clinical Development Portfolio

Pipeline Overview

As of December 31, 2024 · Q4 Update

7Active Programs
2Platform Classes
2Industrial Partners
3Phase 2+ Assets
Small Molecules

Pain

Optimal release kinetics, rapid onset followed by sustained release

Pacira
Discovery
Preclinical
Phase 1
Phase 2
Phase 3

Pain (animal health)

Merck Animal Health
Discovery
Preclinical
Phase 1
Phase 2
Phase 3

Oncology

In-House
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Biologics

Undisclosed

Improved toxicity profile

Undisclosed
Discovery
Preclinical
Phase 1
Phase 2
Phase 3

Platform

In-House
Discovery
Preclinical
Phase 1
Phase 2
Phase 3

Undisclosed

Single injection

Undisclosed
Discovery
Preclinical
Phase 1
Phase 2
Phase 3

Platform

High concentration single injection

In-House
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Completed Stage
Active Stage
Upcoming Stage
PartneredIn-houseUndisclosed

Program progression across clinical development stages. Clinical stages based on US FDA framework. Partners shown reflect current collaboration agreements as of the reporting date.

Platform

Fixed Dose

Fixed Dose

High dose, localized depot for days to weeks therapeutic delivery

Fixed Dose Combo

Fixed Dose Combo

From post-surgical pain to oncology and beyond — we tackle locations conventional delivery struggles to reach.

Smart Materials

Smart Materials

Moving rapidly from bench to bedside: CMC-manufactured human safety data, multi-modal payloads.